Logo

Vertex Collaborates with Mammoth Biosciences to Develop In Vivo Gene-Editing Therapies for Genetic Diseases

Share this
Vertex Collaborates with Mammoth Biosciences to Develop In Vivo Gene-Editing Therapies for Genetic Diseases

Tuba Khan

Vertex Collaborates with Mammoth Biosciences to Develop In Vivo Gene-Editing Therapies for Genetic Diseases

Shots:

  • Mammoth to receive $41M up front- $650M as future payments based upon the achievement of prespecified research- development & commercial milestones across 2 programs & is eligible to receive royalties on sales of any products
  • The collaboration will bolster Vertex’s cell and genetic therapies capabilities with the addition of Mammoth’s ultra-small CRISPR systems to develop in vivo genome editing therapies for patients with serious diseases
  • Mammoth’s CRISPR platform consists of a proprietary toolbox of novel ultra-compact Cas enzymes including Cas14 and Casɸ. The platform is designed to facilitate advanced delivery of in vivo gene-editing for genetic diseases

Click here ­to­ read full press release/ article | Ref: Businesswire | Image: Businesswire

Click Here

Share this article on WhatsApp, LinkedIn and Twitter

We Have a Viewership of 1,00,000 + Views

Join the PharmaShot Family